CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Decongestants are available as pills, liquids, nasal sprays, and nasal drops ... such as antidepressants and medications for asthma and blood pressure. A decongestant called phenylpropanolamine ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric patients, based on data from three independent studies of children and ...

neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

for the treatment of asthma and nasal polyps. Submitting its Marketing Authorization Application with the European Medicines Agency (EMA), the British drugmaker has sought the EU nod for ...